Letter to Louisiana State Legislature Opposing a Bill That Would Weaken the Louisiana State Board of Medical Examiners April 10, 2018
Letter to the HHS Office of Inspector General Requesting an Investigation Into NIH’s Solicitation of Donations From the Alcoholic Beverage Industry for Alcohol Research Study March 19, 2018
Letter to the U.S. House of Representatives Opposing the Newest “False Hope” Legislation March 12, 2018
Panel Presentation at the Johns Hopkins University Bloomberg School of Public Health Symposium: Transparency at the U.S. Food and Drug Administration January 16, 2018
Letter to the U.S. House of Representatives Opposing Senate Bill That Would Provide False Hope to Seriously Ill Patients September 5, 2017
Letter to the FDA About the Agency’s Failure to Provide Timely Notice of an Advisory Committee Meeting April 14, 2017
Comments on the FDA’s Draft Guidance on Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A October 11, 2016
Comments on the FDA’s Draft Guidance on Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B October 11, 2016
Comments on the FDA’s Draft Guidance on Updating Generic Drug Labeling After The Marketing Application For The Reference Listed Drug Has Been Withdrawn September 9, 2016